| Description | Besifovir, a parent drug converted by LB80380, further metabolizes to its active form, LB80317. LB80380 is potent antiviral agent against hepatitis B virus (HBV). |
| In vivo | Besifovir (LB80380) 是一种相对较新的口服非环状核苷酸磷酸盐。涵盖范围：LB80380 是 LB80331 和 LB80317 的前药，口服后快速吸收。Besifovir 的逐渐增加剂量产生血浆浓度的线性提升。超过60mg的剂量对于抑制人体内HBV是有效的。以60mg为例，LB80331在血浆中的最大浓度为397 ng/mL。 |
| molecular weight | 299.22 |
| Molecular formula | C10H14N5O4P |
| CAS | 441785-25-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 250 mg/mL (835.51 mM) |
| References | 1. Mak L Y , Seto W K , Lai C L , et al. Pharmacokinetic evaluation of besifovir for the treatment of HBV infection[J]. Expert Opinion on Drug Metabolism & Toxicology, 2018, 14(1):101-106. |